Relmada Therapeutics Gross Profit

Relmada Therapeutics (RLMD) currently reports a gross profit of $0 as of June 2026. In the prior-year period, the figure was $0. That is below the Consumer Discretionary sector average of $360B. Use the charts on this page to explore Relmada Therapeutics's gross profit history and peer comparisons.

Relmada Therapeutics's gross profit changed from $0 to $0 (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Relmada Therapeutics's gross profit of $0 is lower than the Consumer Discretionary sector average of $360B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Relmada Therapeutics reported $0 in gross profit as of June 2026. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current gross profit of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. The Consumer Discretionary average is $360B. From there, open related valuation or income-statement pages for Relmada Therapeutics, and consider following RLMD for alerts when major investors trade the stock.